Risk factor
Very poor trading liquidity
Profitability factor
Favourable analyst view
About
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBITDA, underv
Target Price
The average target price of GENT.OL is 60 and suggests 66% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre